Oral contraceptive pills are birth control pills including progestin and estrogen hormones. These hormones induce contraception/birth control by preventing ovulation. These pills are also known as combined pills or combined oral contraceptive pills (COCP). Combined oral contraceptive pills are available in five different packs: the 21-day pack, the 24-day pack, the 28-day pack, the 91-day pack and the four-phase regimen. Bayer’s Yaz and Loestrin are the most widely preferred brands of the 24-day pack. Barr Laboratories’ Seasonale and Teva Pharmaceutical Industries’ Seasonique are preferred in the 91-day pack sub-segment. In the four-phase regimen, Bayer’s Natazia dominates the market.
Oral contraceptive pills are the most common form of reversible contraception in the developed economies of the world such as the U.S., Canada, the Western Europe and Australia. Their high effectiveness (99.9% when accurately used and 92% when typically used) and convenience in use (in comparison to contraceptive devices, especially implants), drive the oral contraceptive pills segment.
This report provides in-depth analysis of the global oral contraceptives pills market. The stakeholders for this report include companies involved in the research and development, manufacturing and commercialization of oral contraceptive pills, suppliers and new entrants planning to invest in this market. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition for different oral contraceptive pills in the five major regions.
The market overview section of this report analyzes market dynamics such as drivers, restraints and opportunities that influence the oral contraceptive pills market in the current and future scenario. Further, Porter’s five forces analysis and market attractiveness analysis have been included in market overview section in order to explain the intensity of competition in the market. Porter’s five forces analysis is also elucidated in the section to understand the attractiveness of the oral contraceptive pills market in terms of the five different attributes that have an effect on the sustenance of the players in the oral contraceptive pills market. Competitive scenario among the market players is analyzed through a heat map of major market players in the competitive landscape section of the report. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.
Based on the product types, the global oral contraceptives market is segmented into combination pills, progestin only pills and others. Combination pills are further categorized into three segments including monophasic pills, triphasic pills and others. Market revenue in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 is analyzed for the various types of oral contraceptive pills.
Geographically, the oral contraceptive pills market has been differentiated into five major regions: North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW). This section of the report provides with the market estimation in terms of revenue (US$ Mn) of contraceptive pills market in these five regions from 2013 to 2023. Market revenue for oral contraceptive pills is also provided for geographies along with CAGR % for period 2015 to 2023, considering 2014 as the base year.
This report also includes recommendations section that will assist new companies in establishing their presence and market players in expanding their market share in the oral contraceptive pills market. The report concludes with the company profile section which includes company overview, financial overview, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Actavis, Inc., Bayers AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.
The global oral contraceptive pills market is segmented into the following categories:
Global Oral Contraceptive Pills Market, by Types
- Progestin Only
Global Oral Contraceptive Pills Market, by Category
Global Oral Contraceptive Pills Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest pf APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- Rest of MEA
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
Chapter 2 Executive Summary
2.1 Global Oral Contraceptive Pills Market, by Geography, 2014–2023 (US$ Mn)
2.2 Global Oral Contraceptive Pills Market, by Type, 2014 (US$ Mn)
2.3 Oral Contraceptive Pills Market Snapshot
Chapter 3 Oral Contraceptive Pills Market– Industry Analysis
3.2 Market Drivers
3.2.1 High incident rate of unintended pregnancies is leading to unmet contraceptive needs
3.2.2 Awareness programs by government and NGOs are promoting the use of contraceptive pills globally
3.2.3 Increasing maternal age and late pregnancies
3.3.1 Side effects associated with the use of contraceptive drugs
3.4.1 Ethical and social issues restrict the use or subsidies on contraceptives in some countries
3.4.2 Presence of large unmet contraceptive needs in emerging Asian and African countries
3.5 Porter’s Five Forces Analysis
3.6 Market Attractiveness Analysis– Oral Contraceptive Pills Market, by Geography (2014) (%)
3.7 Heat Map Analysis, by Key Players, 2014
3.8 Adoption and Prescription Pattern Analysis
3.9 Market Scenario of Oral Contraceptive Pills
Chapter 4 Market Segmentation – By Type
4.2 Global Oral Contraceptive Pills Market Revenue, by Type, 2013–2023 (US$ Mn)
4.3 Global Combination Pills Market Revenue, 2013–2023 (US$ Mn)
4.3.1 Global Monophasic Pills Market Revenue, 2013–2023 (US$ Mn)
4.3.2 Global Triphasic Pills Market Revenue, 2013–2023 (US$ Mn)
4.3.3 Global Other Combination Pills Market Revenue, 2013–2023 (US$ Mn)
4.4 Global Progestin Only Pills Market Revenue, 2013–2023 (US$ Mn)
4.5 Global Other Pills Market Revenue, 2013–2023 (US$ Mn)
Chapter 5 Market Segmentation – By Category
5.2 Global Oral Contraceptive Pills Market Revenue, by Category, 2013–2023 (US$ Mn)
5.3 Global Generic Oral Contraceptive Pills Market Revenue, 2013–2023 (US$ Mn)
5.4 Global Branded Oral Contraceptive Pills Market Revenue, 2013–2023 (US$ Mn)
Chapter 6 Market Segmentation – By Geography
6.2 Global Oral Contraceptive Pills Market Revenue, by Geography, 2013–2023 (US$ Mn)
6.3 North America Oral Contraceptive Pills Market Revenue, by Country, 2013–2023 (US$ Mn)
6.4 Europe Oral Contraceptive Pills Market Revenue, by Country, 2013–2023 (US$ Mn)
6.5 Asia Pacific Oral Contraceptive Pills Market Revenue, by Country, 2013–2023 (US$ Mn)
6.6 LATAM Oral Contraceptive Pills Market Revenue, by Country, 2013–2023 (US$ Mn)
6.7 MEA Oral Contraceptive Pills Market Revenue, by Country, 2013–2023 (US$ Mn)
Chapter 7 Company Profiles
7.1 Allergan, plc (Actavis)
7.2 Bayer AG
7.3 Janssen Global Services, LLC
7.4 Mankind Pharma Ltd.
7.5 Merck & Co., Inc.
7.6 Pfizer, Inc.
7.7 Piramal Enterprises Ltd.
7.8 Teva Pharmaceutical Industries Ltd
Contraceptive or birth control pill is a daily pill that contains hormones to change the way the body works and prevent pregnancy. Two main types of oral contraceptive pills are available in the market: combination pill containing two hormones (estrogen and progestin) and progestin-only pill. High incidence of unintended pregnancies and awareness programs organized by governments and NGOs drive the global demand for oral contraceptive pills. Moreover, increasing maternal age and late pregnancies coupled with family planning by most couples have triggered the growth of the market.
Based on the types of products, the global oral contraceptive pills market has been categorized into combination pills, progestin only pills and others. Combination pills are type of oral contraceptive pills that contain progestin and ethinyl estradiol that are similar to natural sex hormones estrogen and progesterone produced in a woman’s body. Combination pills are further segmented into monophasic, triphasic, and other (biphasic and quadriphasic) based on the level of hormones present among females during the first three weeks of the menstrual cycle. The monophasic combination pills sub-segment accounted for nearly majority of the market share of the combination pills segment in 2014 due to higher effectiveness and growing preference for monophasic pills. Monophasic pills are available in three different doses of estrogen: low dose (20 mcg), regular dose (30 mcg to 35 mcg), and high dose (50 mcg). Low estrogen monophasic pills cause less bloating or breast tenderness. Hence, most women consider monophasic pill as a first line of choice for contraception.
Based on category, the global oral contraceptive pills market has been segmented into branded and generic oral contraceptive pills. Globally, the market is dominated by generic contraceptive pills due to availability of cost effective (low cost) drugs with similar bioavailability and bioequivalence as the branded drugs, rising preference for generic drugs among patients, and growing awareness about unintended pregnancies. This situation is more intense in the developing nations in Asia Pacific. The market in the region is expected to expand at the highest CAGR during the forecast period.
Geographically, the global contraceptive pills market has been differentiated into the following regions: North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America dominated the global contraceptive pills market in 2014 due to the high incidence rate of unintended pregnancies, availability of favorable reimbursement policies after implementation of the Affordable Care Act and increased use of emergency contraceptive pills and oral contraceptive pills. On the other hand, Asia Pacific is estimated as the most opportunistic market during the forecast period due to strong economic growth in countries such as India, China, Singapore, Philippines, Australia, and others. This in turn, has led to increased awareness about the use of contraception for pregnancy prevention, rising disposable income and demand for healthy life, which is increasing the adoption rate of contraceptive pills in Asia Pacific.
The global contraceptive pills market is characterized by the presence of major companies such as Actavis, Inc., Bayer AG, Church & Dwight, Co., Inc., Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mankind Pharma, and Piramal Enterprises Ltd. These market players are engaged in growth strategies such as acquisitions, marketing of products (providing free samples or contraceptives in reduced prices) and introducing various awareness programs to increase the market share and sustain in the highly competitive contraceptive pills market.